Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL246 Target Snapshot

Beta-3 adrenergic receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,161Compounds
372Assays
53Approved Drugs
3,769.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Beta-3 adrenergic receptor shows approved-linked disease relevance led by overactive bladder. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P13945. Start with overactive bladder, then reuse UniProt P13945 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with overactive bladder, then reuse UniProt P13945 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
overactive bladder

Beta-3 adrenergic receptor shows approved-linked disease relevance led by overactive bladder. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with overactive bladder because it currently carries approved-linked support. Linked drugs include MIRABEGRON, RITOBEGRON, SOLABEGRON, VIBEGRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-3 adrenergic receptor as ChEMBL target CHEMBL246, mapped to UniProt P13945. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-3 adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL246
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P13945
Beta-3 adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Beta-3 adrenergic receptor is the right protein anchor across sources, using UniProt P13945 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why overactive bladder is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBeta-3 adrenergic receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP13945
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelBeta-3 adrenergic receptor
UniProt AccessionP13945
Component TypeProtein
Sequence Length408 aa

Beta-3 adrenergic receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Beta-3 adrenergic receptor, mapped to UniProt P13945. Sequence length is 408 aa.

Mapped IDP13945
Review nameBeta-3 adrenergic receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Beta-3 adrenergic receptor shows approved-linked disease relevance led by overactive bladder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
overactive bladder
4 linked drugs · 4 direct · 4 efficacy
Linked drugMIRABEGRON
Linked drugRITOBEGRON
Linked drugSOLABEGRON
Linked drugVIBEGRON
Approved-linked Approved
Polyuria
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIRABEGRON
Linked drugVIBEGRON
Approved-linked Approved
urgency urinary incontinence
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIRABEGRON
Linked drugVIBEGRON
Approved-linked Approved
Urinary incontinence
2 linked drugs · 2 direct · 2 efficacy
Linked drugMIRABEGRON
Linked drugVIBEGRON
Late clinical Phase III
chronic interstitial cystitis
1 linked drug · 1 direct · 1 efficacy
Linked drugMIRABEGRON
Late clinical Phase III
nephrolithiasis
1 linked drug · 1 direct · 1 efficacy
Linked drugMIRABEGRON
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with overactive bladder because it currently carries approved-linked support. Linked drugs include MIRABEGRON, RITOBEGRON, SOLABEGRON, VIBEGRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseoveractive bladder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

53
Approved
4
Phase III
21
Phase II
Assay Mix

Activity Type Distribution

IC50898.0
KI1,222.0
EC501,571.0
KD78.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL279260 10.8 EC50 0.016 Clinical
CHEMBL1257555 10.7 EC50 0.02 Preclinical
CHEMBL446806 10.54 EC50 0.029 Preclinical
CHEMBL529659 10.46 EC50 0.035 Preclinical
CHEMBL470857 10.46 EC50 0.035 Preclinical
CHEMBL1257675 10.4 EC50 0.04 Preclinical
CHEMBL3128199 10.4 EC50 0.04 Preclinical
CHEMBL453322 10.39 EC50 0.041 Preclinical
CHEMBL509156 10.38 EC50 0.042 Preclinical
CHEMBL550871 10.36 EC50 0.044 Preclinical
Distribution

pChEMBL Value Distribution

108
5.0
117
5.5
191
6.0
194
6.5
309
7.0
299
7.5
292
8.0
182
8.5
131
9.0
56
9.5
pChEMBL
Approved Drugs

Approved Drugs

VIBEGRON
CHEMBL2107826
Approved 2018
Properties Compare Identifier
MIRABEGRON
CHEMBL2095212
Approved 2012
Properties Compare Identifier
FORMOTEROL
CHEMBL1256786
Approved 2001
Properties Compare Identifier
CARVEDILOL
CHEMBL723
Approved 1995
Properties Compare Identifier
SALMETEROL
CHEMBL1263
Approved 1994
Properties Compare Identifier
PROPAFENONE
CHEMBL631
Approved 1989
Properties Compare Identifier
LEVOBUNOLOL
CHEMBL1201237
Approved 1985
Properties Compare Identifier
PINDOLOL
CHEMBL500
Approved 1982
Properties Compare Identifier
TIMOLOL
CHEMBL499
Approved 1978
Properties Compare Identifier
PROPRANOLOL
CHEMBL27
Approved 1967
Properties Compare Identifier
EPINEPHRINE
CHEMBL679
Approved 1965
Properties Compare Identifier
ISOPROTERENOL
CHEMBL434
Approved 1956
Properties Compare Identifier
NOREPINEPHRINE
CHEMBL1437
Approved 1950
Properties Compare Identifier
FENOTEROL
CHEMBL32800
Properties Compare Identifier
Assay Landscape

Assay Landscape

372
Total Assays
1,251
Tested Compounds
3
Assay Types
Functional — 212 assays, 1,251 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 142 1,063 7.8
assay format 66 188 7.6
cell membrane format 3 0 —
organism-based format 1 0 —
Binding — 158 assays, 512 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 116 138 7.2
cell-based format 40 308 6.6
assay format 1 35 4.7
cell membrane format 1 31 5.7
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine